Theragen Etex Co Ltd
KOSDAQ:066700
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
T
|
Theragen Etex Co Ltd
KOSDAQ:066700
|
103.3B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
Theragen Etex Co Ltd
Glance View
THERAGEN ETEX Co., Ltd. engages in the manufacture and sale of pharmaceutical products and in the provision of genome sequencing services. The company is headquartered in Ansan, Gyeonggi-Do. The company went IPO on 2004-05-27. is a Korea-based company engaged in the industrial equipment business, healthcare and genome business and pharmaceutical business. The firm operates its business through three divisions: flat panel display (FPD) manufacturing equipment division, which provides loading and unloading systems, printed circuit board (PCB) bonding systems, battery washing lines and laser systems; healthcare and genome division engages in the provision of genome analysis services and others, and pharmaceutical division engages in the manufacture of digestive system remedies, antibiotics, remedies for fever, circulatory system remedies, respiration system remedies, treatment for chronic hepatitis, diabetes remedies, psychotropic agents, osteoporosis treatments and others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Theragen Etex Co Ltd is 51.7%, which is above its 3-year median of 48.1%.
Over the last 3 years, Theragen Etex Co Ltd’s Gross Margin has increased from 39.9% to 51.7%. During this period, it reached a low of 39.9% on Aug 30, 2022 and a high of 51.7% on Oct 30, 2025.
